Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

Supporting evidence

• Evaluation report

• Committee papers (PDF 14.7 MB)

  Published:

  26 May 2021